Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28543276 | 0.81 | ALDH1A1 (0.47) | KMT2AALDH1A1 | |
| SCHEMBL19125641 | 0.81 | DRD2 (0.56) | KMT2AALDH1A1MEN1 | |
| SCHEMBL2592594 | 0.81 | DRD2 (0.56) | KMT2AALDH1A1MEN1 | |
| SCHEMBL3637783 | 0.77 | KMT2A (0.64) | KMT2ACHRM2ALDH1A1MEN1POLB | |
| SCHEMBL16641032 | 0.76 | ATM (0.54) | KMT2AALDH1A1MEN1 | |
| SCHEMBL415949 | 0.75 | CHRM2 (0.67) | KMT2ACHRM2ALDH1A1MEN1POLB | |
| SCHEMBL1499186 | 0.74 | MAOB (0.42) | KMT2AALDH1A1MEN1POLB | |
| SCHEMBL27558716 | 0.74 | CXCR4 (0.56) | KMT2AALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL27558694 | 0.73 | CXCR4 (0.55) | KMT2AALDH1A1MEN1 | |
| SCHEMBL19555228 | 0.73 | KMT2A (0.46) | KMT2ACHRM2ALDH1A1HRH3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107698533-B | Method for preparing linezolid | 浙江海翔川南药业有限公司 | 2021-03-26 | — | — | CN | disclosed |
| EP-2899185-B1 | Processes for preparing linezolid | UNIV INDIANA RES & TECH CORP (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9656973-B2 | Processes for preparing linezolid | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-05-23 | — | — | US | disclosed |
| US-9562040-B2 | Processes for preparing Rivaroxaban | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-02-07 | — | — | US | disclosed |
| EP-2563781-B1 | PROCESSES FOR PREPARING LINEZOLID | UNIV INDIANA RES & TECH CORP (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160024032-A1 | PROCESSES FOR PREPARING LINEZOLID | UNIV INDIANA RES & TECH CORP (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2899185-A1 | Processes for preparing linezolid | Indiana University Research and Technology Corporation (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20150175590-A1 | PROCESSES FOR PREPARING RIVAROXABAN | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2015-06-25 | — | — | US | disclosed |
| EP-2563781-A1 | PROCESSES FOR PREPARING LINEZOLID | Indiana University Research and Technology Corporation (US) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011137222-A1 | PROCESSES FOR PREPARING LINEZOLID | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175590-A1 | PROCESSES FOR PREPARING RIVAROXABAN | VKORC1, VKORC1L1, CYP2C9 | KMT2A 1901/4885CHRM2 1709/4885ALDH1A1 1530/4885 |
| US-20160024032-A1 | PROCESSES FOR PREPARING LINEZOLID | CYP2C9, CYP2C19, CYP3A43 | KMT2A 958/4885CHRM2 4872/4885ALDH1A1 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.